Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Total Non-Current Liabilities (2022 - 2025)

TriSalus Life Sciences (TLSI) has 4 years of Total Non-Current Liabilities data on record, last reported at $59.1 million in Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 42.22% year-over-year to $59.1 million; the TTM value through Dec 2025 reached $59.1 million, up 42.22%, while the annual FY2025 figure was $59.1 million, 42.22% up from the prior year.
  • Total Non-Current Liabilities reached $59.1 million in Q4 2025 per TLSI's latest filing, up from $58.2 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $59.1 million in Q4 2025 and bottomed at $19.6 million in Q3 2023.
  • Average Total Non-Current Liabilities over 4 years is $42.6 million, with a median of $41.5 million recorded in 2024.
  • Peak YoY movement for Total Non-Current Liabilities: fell 2.71% in 2023, then skyrocketed 110.42% in 2024.
  • A 4-year view of Total Non-Current Liabilities shows it stood at $33.9 million in 2022, then decreased by 2.71% to $33.0 million in 2023, then grew by 25.79% to $41.5 million in 2024, then soared by 42.22% to $59.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $59.1 million in Q4 2025, $58.2 million in Q3 2025, and $53.2 million in Q2 2025.